Fmoc-2-氨基-1,2,3,4-四氢-萘-2-羧酸 | 135944-08-0

• 物质功能分类: 生物化工 - 生化试剂 - 氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: Fmoc-2-氨基-1,2,3,4-四氢-萘-2-羧酸
• 中文别名: 2-((((9H-芴-9-基)甲氧基)羰基)氨基)-1,2,3,4-四氢萘-2-羧酸；N-FMOC-DL-2-氨基四氢萘-2-羧酸
• 英文名称: N^α-Fmoc-(D,L)-2-aminotetralin-2-carboxylic acid
• 英文别名: Fmoc-amino-1,2,3,4-tetrahydro-2-naphthyl carboxylic acid；Fmoc-D,L-Atc-OH；(rac)-Fmoc-2-amino-tetrahydro-2-naphthyl carboxylic acid；Fmoc-Atc-OH；fmoc-(D,L)-2-Aminotetraline-2-carboxylic acid；2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid；2-(9H-fluoren-9-ylmethoxycarbonylamino)-3,4-dihydro-1H-naphthalene-2-carboxylic acid
• CAS: 135944-08-0
• 化学式: C₂₆H₂₃NO₄
• 分子量: 413.473
• InChiKey: PRKGWEACQDXDDT-UHFFFAOYSA-N

物化性质

• 熔点：
  177-181 °C
• 沸点：
  532.63°C (rough estimate)
• 密度：
  1.2217 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S24/25
• 海关编码：
  2924299090
• 储存条件：
  存储条件：2-8℃，请保持干燥并密封。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Fmoc-d,l-2-aminotetralin-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H410: Very toxic to aquatic life with long lasting effects
P273: Avoid release to the environment

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Fmoc-d,l-2-aminotetralin-2-carboxylic acid
CAS number: 135944-08-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C26H23NO4
Molecular weight: 413.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Fmoc-2-氨基-1,2,3,4-四氢-萘-2-羧酸 在 吡啶 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 {2-[3-(tert-Butoxycarbonyl-{4-[tert-butoxycarbonyl-(3-tert-butoxycarbonylamino-propyl)-amino]-butyl}-amino)-propylcarbamoyl]-1,2,3,4-tetrahydro-naphthalen-2-yl}-carbamic acid 9H-fluoren-9-ylmethyl ester
  参考文献：
  名称：

  philanthotoxins氨基酸部分的构象限制和空间体积对AMPAR拮抗作用的影响。

  摘要：

  Philanthotoxin-343（PhTX-343）是黄蜂毒素PhTX-433的合成类似物，是离子型受体（例如AChR或iGluR）的非竞争性拮抗剂。为了确定氨基酸侧链变异的可能影响，制备了由17种PhTX-343类似物组成的文库。因此，酪氨酸被非极性，构象受限或庞大的氨基酸取代，而酰基单元和多胺部分保持不变。首次制备了具有叔酰胺基团的类似物。将五氟苯基酯用于酰胺键的形成，建立了费洛托辛溶液和固相合成的通用方案（总收率分别为39-90％和42-54％）。测试了这些类似物拮抗海藻酸盐诱导的爪蟾卵母细胞表达的大鼠脑mRNA的2-氨基-3-（3-羟基-5-甲基-4-异恶唑酰基）丙酸受体（AMPAR）的海因酸盐诱导电流的能力。这表明氨基酸部分中的空间体积被很好地耐受，并且表明与AMPAR的结合不涉及作为氢键供体的α-NHCO基团。

  DOI：

  10.1021/jm049906w

文献信息

• Melanocortin receptor ligands
  申请人：Ebetino Hallock Frank

  公开号：US20060128613A1

  公开（公告）日：2006-06-15

  Disclosed are MC-4 and/or MC-3 receptor ligands, the ligands having a structure according to Formula (I): wherein R 2 , R 4 , R 4′ , R 5 , R 6 , R 6′ , R 7 , R 8 , R 8′ , R 9 , R 9′ , R 10 , Ar, Z 1 , Z 2 , Z 3 , X, B, D, p, q, r and s are as described in the specification and claims, and optical isomers, diastereomers or enantiomers thereof; pharmaceutically-acceptable salts, hydrates, and biohydrolyzable esters, amides or imides thereof. Also disclosed are pharmaceutical compositions comprising the ligands of Formula (I), as well as methods of treating diseases mediate by the MC-4/MC-3 receptors, as described in the Detailed Descriptions section of the specification.

  公开了MC-4和/或MC-3受体配体，该配体具有按照式（I）的结构：其中R2、R4、R4'、R5、R6、R6'、R7、R8、R8'、R9、R9'、R10、Ar、Z1、Z2、Z3、X、B、D、p、q、r和s如说明书和索赔中所述，以及其光学异构体、二对映异构体或对映体；药用盐、水合物和生物水解酯、酰胺或亚酰胺。还公开了包括式（I）配体的药物组合物，以及治疗由MC-4/MC-3受体介导的疾病的方法，如说明书的详细描述部分所述。
• Structure−Activity Relationships of the Melanocortin Tetrapeptide Ac-His-<scp>d</scp>-Phe-Arg-Trp-NH₂ at the Mouse Melanocortin Receptors. 4. Modifications at the Trp Position
  作者：Jerry Ryan Holder、Zhimin Xiang、Rayna M. Bauzo、Carrie Haskell-Luevano

  DOI：10.1021/jm020296e

  日期：2002.12.1

  possessed nanomolar MC1R and MC5R potency but micromolar MC3R and MC4R agonist potency. Additionally, these studies identified that substitution of the Trp amino acid with either Nal(2') or D-Nal(2') resulted in equipotent melanocortin receptor potency, suggesting that the chemically reactive Trp indole side chain may be replaced with the nonreactive Nal(2') moiety for the design of nonpeptide melanocortin

  黑皮质素途径参与几种生理功能的调节，包括皮肤色素沉着，类固醇生成，肥胖，能量稳态和外分泌腺功能。该黑皮质素途径由五个已知的G蛋白偶联受体，源自proopiomelanocortin（POMC）基因转录物的内源激动剂，内源性拮抗剂Agouti和Agouti相关蛋白（AGRP）组成，并通过细胞内cAMP信号转导途径发出信号。内源性黑皮质素激动剂包含推定的信息序列“ His-Phe-Arg-Trp”，假定其对黑皮质素受体分子的识别和刺激很重要。在此，我们报告了基于模板Ac-His-D-Phe-Arg-Trp-NH（2）的四肽文库，由20个成员组成，这些成员在Trp（9）位置（alpha-MSH编号）已被修饰，并在药理上表征了小鼠黑皮质素受体MC1R，MC3R，MC4R和MC5R的激动剂活性。这项研究的结果产生了化合物，其药理学性质从等效性到最高100 microM浓度的黑皮质素受体活性丧失。有趣
• Probes, systems, and methods for drug discovery
  申请人：——

  公开号：US20030125315A1

  公开（公告）日：2003-07-03

  Aspects of the present invention include probes, methods, systems that have stand alone utility and may comprise features of a drug discovery system or method. The present invention also includes pharmaceutical compositions. In more detail, the present invention provides molecular probes and methods for producing molecular probes. The present invention provides also provides systems and methods for new drug discovery. An embodiment of the present invention utilizes sets of probes of the present invention and a new approach to computational chemistry in a drug discovery method having increased focus in comparison to heretofore utilized combinatorial chemistry. The present invention also provides computer software and hardware tools useful in drug discovery systems. In an embodiment of a drug discovery method of the present invention in silico methods and in biologico screening methods are both utilized to maximize the probability of success while minimizing the time and number of wet laboratory steps necessary to achieve the success.

  本发明的方面包括探针、方法、系统，具有独立实用性并可能包括药物发现系统或方法的特征。本发明还包括制药组合物。更详细地说，本发明提供了分子探针和制备分子探针的方法。本发明还提供了新药物发现的系统和方法。本发明的实施例利用本发明的探针集和一种新的计算化学方法在药物发现方法中具有更高的聚焦度，相比之前使用的组合化学方法。本发明还提供了在药物发现系统中有用的计算机软件和硬件工具。在本发明的药物发现方法的实施例中，同时利用了基于计算机的方法和生物筛选方法，以最大化成功的可能性，同时最小化必要的湿实验步骤的时间和数量。
• Probes, Systems, and Methods for Drug Discovery
  申请人：Mjalli Adnan M. M.

  公开号：US20110039714A1

  公开（公告）日：2011-02-17

  Aspects of the present invention include probes, methods, systems that have stand alone utility and may comprise features of a drug discovery system or method. The present invention also includes pharmaceutical compositions. In more detail, the present invention provides molecular probes and methods for producing molecular probes. The present invention provides also provides systems and methods for new drug discovery. An embodiment of the present invention utilizes sets of probes of the present invention and a new approach to computational chemistry in a drug discovery method having increased focus in comparison to heretofore utilized combinatorial chemistry. The present invention also provides computer software and hardware tools useful in drug discovery systems. In an embodiment of a drug discovery method of the present invention in silico methods and in biologico screening methods are both utilized to maximize the probability of success while minimizing the time and number of wet laboratory steps necessary to achieve the success.

  本发明的方面包括探针、方法、系统，具有独立实用性，并可能包括药物发现系统或方法的特征。本发明还包括制药组合物。更详细地说，本发明提供了分子探针和制备分子探针的方法。本发明还提供了用于新药物发现的系统和方法。本发明的一种实施利用本发明的探针集和一种新的计算化学方法，在药物发现方法中具有比迄今所使用的组合化学更高的聚焦度。本发明还提供了在药物发现系统中有用的计算机软件和硬件工具。在本发明的药物发现方法的实施中，利用无机方法和生物筛选方法最大化成功的可能性，同时最小化实现成功所需的时间和实验室步骤数量。
• Anthranilimide-based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes: 1. Identification of 1-amino-1-cycloalkyl carboxylic acid headgroups
  作者：Steven M. Sparks、Pierette Banker、David M. Bickett、H. Luke Carter、Daphne C. Clancy、Scott H. Dickerson、Kate A. Dwornik、Dulce M. Garrido、Pamela L. Golden、Robert T. Nolte、Andrew J. Peat、Lauren R. Sheckler、Francis X. Tavares、Stephen A. Thomson、Liping Wang、James E. Weiel

  DOI：10.1016/j.bmcl.2008.11.085

  日期：2009.2

  Optimization of the amino acid residue within a series of anthranilimide-based glycogen phosphorylase inhibitors is described. These studies culminated in the identification of anthranilimides 16 and 22 which displayed potent in vitro inhibition of GPa in addition to reduced inhibition of CYP2C9 and excellent pharmacokinetic properties. (C) 2008 Elsevier Ltd. All rights reserved.